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Cleft palate is a common birth defect in humans. Elevation and fusion of paired palatal
shelves are coordinated by growth and transcription factors, and mutations in these
can cause malformations. Among the effector genes for growth factor signaling are
extracellular matrix (ECM) glycoproteins. These provide substrates for cell adhesion
(e.g., fibronectin, tenascins), but also regulate growth factor availability (e.g., fibrillins).
Cleft palate in Bmp7 null mouse embryos is caused by a delay in palatal shelf elevation. In
contrast, palatal shelves of Tgf-β3 knockout mice elevate normally, but a cleft develops due
to their failure to fuse. However, nothing is known about a possible functional interaction
between specific ECM proteins and Tgf-β/Bmp family members in palatogenesis. To
start addressing this question, we studied the mRNA and protein distribution of relevant
ECM components during secondary palate development, and compared it to growth
factor expression in wildtypewild type and mutant mice. We found that fibrillin-2 (but
not fibrillin-1) mRNA appeared in the mesenchyme of elevated palatal shelves adjacent
to the midline epithelial cells, which were positive for Tgf-β3 mRNA. Moreover, midline
epithelial cells started expressing fibronectin upon contact of the two palatal shelves.
These findings support the hypothesis that fibrillin-2 and fibronectin are involved in
regulating the activity of Tgf-β3 at the fusing midline. In addition, we observed that
tenascin-W (but not tenascin-C) was misexpressed in palatal shelves of Bmp7-deficient
mouse embryos. In contrast to tenascin-C, tenascin-W secretion was strongly induced by
Bmp7 in embryonic cranial fibroblasts in vitro. These results are consistent with a putative
function for tenascin-W as a target of Bmp7 signaling during palate elevation. Our results
indicate that distinct ECM proteins are important for morphogenesis of the secondary
palate, both as downstream effectors and as regulators of Tgf-β/Bmp activity.
Keywords: palate morphogenesis, growth factors, transforming growth factor beta, bone morphogenetic protein,
extracellular matrix, fibronectin, tenascin, fibrillin1
INTRODUCTION
In mammals, morphogenesis of the secondary palate starts with
the formation of two palatal shelves that grow out ventrally from
the maxillary processes on both sides of the tongue (Meng et al.,
2009; Iwata et al., 2011). On embryonic day 14–15 in the mouse
and in the ninth week of pregnancy in humans, the two vertically
oriented palatal shelf anlagen rapidly elevate into a horizontal
position, followed by their apposition at the midline. Later, the
epithelia of two matching palatal shelves disintegrate in the mid-
line, leading to the fusion of their mesenchymal compartments.
In mouse mutant embryos, cleft palate can be caused either
directly by disturbed growth, elevation or fusion of the palatal
shelves, or indirectly, e.g., by malformations or impaired motil-
ity of the lower jaw and the tongue (Meng et al., 2009; Iwata
et al., 2011). Malformations of the upper lip and the secondary
palate are among the most frequent birth defects in humans
(Mossey et al., 2009). In a high percentage the causes remain
unknown, but both environmental (teratogenic) and hereditary
factors might contribute (Meng et al., 2009; Iwata et al., 2011).
An increasing number of regulatory genes have been linked to
cleft lip and palate (CLP) in humans. For example, dominant
mutations of transcription factor IRF6 are responsible for Van der
Woude Syndrome, whereas recessive mutations in the same gene
cause non-syndromic cleft palate (Kondo et al., 2002). In other
cases of CLP in humans, mutations have been found, e.g., in the
genes for homeobox transcription factor MSX1 (Alappat et al.,
2003), and very recently for growth factor BMP7 (Wyatt et al.,
2010). Genetic studies have linked polymorphisms in the human
genes for growth factors TGF-α and Tgf-β3, nuclear receptor
RAR-α, and growth factor receptor FGFR1 to CLP (Mossey et al.,
2009). As expected, mice deficient for Irf6, Msx1, Tgf-β3, or
Bmp7 partially or completely mimic the cleft palate phenotype
of humans with mutations or polymorphisms in these genes
(Satokata and Maas, 1994; Proetzel et al., 1995; Ingraham et al.,
2006; Zouvelou et al., 2009a). Concerning the mechanism of cleft
palate formation, it is known that Tgf-β3 is required for the
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fusion of the palatal shelves (Proetzel et al., 1995; Taya et al.,
1999). Whereas earlier work indicated that this growth factor
stimulates epithelial-mesenchymal transformation at the palatal
midline via transcription factors Smad2f/Lef1 (Nawshad andHay,
2003), more recent evidence shows that Tgf-β3 signalingmediates
palatal fusion mainly or exclusively by inducing apoptosis of mid-
dle edge epithelial (MEE) cells (Xu et al., 2006; Nawshad, 2008;
Huang et al., 2011). In contrast, in embryos deficient for Bmp7,
another member of the Tgf-β family, the elevation of palatal
shelves seems to be disturbed (Zouvelou et al., 2009a), pointing
to a defect in cell division, reorganization, and/or ECM pro-
duction. For both human and mouse malformations, however,
practically nothing is known about the downstream effectors of
the mutated genes. Thus, the cellular mechanisms by which these
regulatory genes finally cause a specific morphogenetic defect are
not known as yet.
Extracellular matrix (ECM) is essential for tissue integrity by
forming a stable framework to which cells adhere via integrin
receptors (Alberts et al., 2008). During development and regener-
ation, ECM is constantly remodeled by growth factor controlled
synthesis and proteolysis by matrix-degrading enzymes (Mott
and Werb, 2004; Larsen et al., 2006). Whereas fibrillar collagens
and large proteoglycans are major structural entities of ECM,
more minor ECM components have important regulatory func-
tions: they promote cell adhesion (fibronectin, laminin) (Alberts
et al., 2008), modulate cell spreading and motility (tenascins)
(Chiquet-Ehrismann and Chiquet, 2003), control collagenmatrix
assembly (FACIT collagens) (Zhang et al., 2005), or store growth
factors and present them to cells (fibrillins) (Kaartinen and
Warburton, 2003). Not much has been published yet about the
function of ECM in secondary palate formation, although early
reports recognized its importance (Morris-Wiman and Brinkley,
1992). Tenascin-C was implied due to its striking expression pat-
tern during palatogenesis (Ferguson, 1988), but these studies were
not continued. Other early work tried to establish a causal link
between elevation of the palatal shelves and a rapid accumu-
lation of hyaluronan (reviewed in Ferguson, 1988), but again
these studies were not pursued. A more recent paper implied
a Tgf-β3-induced chondroitin sulphate proteoglycan in palatal
shelf adhesion, but its exact molecular identity was not deter-
mined (Gato et al., 2002). Thus, surprisingly little is known about
the functional role of ECM in palatogenesis.
ECM genes are important transcriptional targets for
Tgf-β/Bmp family members (Verrecchia and Mauviel, 2007;
Tucker and Chiquet-Ehrismann, 2009). Interestingly, different
members of the Tgf-β family can regulate even closely related
ECM proteins in distinct ways. For example, tenascin-C expres-
sion is induced by Tgf-β1 but not Bmp2, whereas tenascin-W
is regulated in the opposite manner (Tucker and Chiquet-
Ehrismann, 2009), indicating that growth factor signaling can
affect the balance of local ECM composition. Tenascins are
structurally related to fibronectin, but have a quite opposite
mode of action: whereas fibronectin promotes cell adhesion
(Alberts et al., 2008), tenascins interfere with fibronectin func-
tion (Chiquet-Ehrismann et al., 1988; Huang et al., 2001). Thus,
tenascins are anti-adhesive and pro-migratory, and their aberrant
regulation due to the lack of a specific growth factor might change
cell-ECM interactions and induce a specific malformation. To
give another example, certain ECM components are important
for the presentation and bioavailability of growth factors, e.g.,
fibrillins (Kaartinen and Warburton, 2003) and fibronectin
(Dallas et al., 2005; Fontana et al., 2005) for Tgf-βs and Bmps, or
proteoglycans for fibroblast growth factors (Iozzo et al., 2009).
Faulty expression of an ECM component in the absence of one
growth factor might thus disturb signaling by others.
However, a physical or functional interaction between Tgf-
β/Bmp growth factors and specific ECM components during
morphogenesis of the secondary palate has not been studied so
far. In a first step to address this question, we describe here the
specific expression patterns of fibrillin-1, fibrillin-2, fibronectin,
tenascin-C, and tenascin-W mRNAs during craniofacial develop-
ment of mouse embryos between E13.5 and E15.5 using in situ
hybridization, and compare them to those of Tgf-β1 and Tgf-β3.
MATERIALS AND METHODS
ANIMALS, EMBRYONIC TISSUE, AND CRYOSECTIONING
C57BL/6 wildtype mouse embryos were obtained from J.-F. Spetz
at the Friedrich-Miescher Institute for Biomedical Research in
Basel, Switzerland. The Bmp7 null allele of Bmp7 heterozygous
null mice was generated by Cre-mediated recombination in the
germ line of a conditional Bmp7 allele (Bmp7flx), in which
exon 1 is flanked by loxP sites as described earlier (Zouvelou
et al., 2009b). Bmp7 heterozygous null mice were intercrossed
to obtain Bmp7+/+, Bmp7+/− and Bmp7−/− embryos from the
same litter. After mating, appearance of a vaginal plug was taken
as embryonic day 0.5 (E0.5). Pregnant females were sacrificed by
cervical dislocation at the desired stage (E13.5–E14.5), embryos
were removed from the uterus and decapitated. Genotyping
of embryos was carried out by allele-specific PCR. All proce-
dures were approved by the Cantonal Veterinary Offices of Basel
and Zurich, Switzerland. The embryo heads were washed in
ice-cold phosphate buffered saline (PBS; 150mM NaCl, 20mM
Na-phosphate, pH 7.4), fixed in 4% paraformaldehyde in PBS
overnight, washed briefly in PBS, soaked for 24 h in 30%
sucrose in PBS, embedded in Tissue Tek (O.C.T. compound;
Sakura Finetek Europe B.V., Zoeterwoude, Netherlands), and
frozen on a metal block cooled to −80◦C. All tissue was stored
at −80◦C before sectioning. Serial frontal sections (10–12μm
thick) of the embryo heads were prepared on a Cryocut E
cryomicrotome (Reichert-Jung, Leica Microsystems, Heerbrugg,
Switzerland), dried at 37◦C for 1–5min, and stored at −80◦C
before further use.
GENE-SPECIFIC RNA PROBES AND in situ HYBRIDIZATION
Total RNA was isolated from E14.5 C57BL/6 wildtype mouse
embryos or from mouse embryo fibroblasts (Maier et al.,
2008) using an RNAeasy Mini Kit (Qiagen, Hombrechtikon,
Switzerland), and reverse transcribed to cDNA using Moloney
murine leukemia virus reverse transcriptase (Promega,
Dübendorf, Switzerland). Gene specific primers (Microsynth,
Balgrach, Switzerland) were designed using a program provided
by NCBI (http://www.ncbi.nlm.nih.gov/tools/primer-blast/
index.cgi?LINK_LOC=BlastHome), and fitted with BamH1
(forward primers) or HindIII (reverse primers) restriction sites
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at their 5′ ends, respectively (Table 1). Using these primers and
mouse cDNA as a template, specific products were amplified by
PCR using Go Taq polymerase (Promega), cut with respective
restriction enzymes, and cloned into pBluescript SK+ plasmid
(Stratagene/Agilent, Santa Clara, USA). Plasmids encoding
mouse tenascin-C and -W cDNAs were obtained from R.
Chiquet-Ehrismann (Friedrich Miescher Institute for Biomedical
Research, Basel, Switzerland). Digoxygenin-labeled anti-sense
and sense RNA probes were generated with a labeling kit from
Roche Diagnostics (Koch et al., 1995). The labeled probes were
used for in situ hybridization as published in detail before (Fluck
et al., 2000). In preliminary experiments, serial frontal sections
were hybridized with individual probes. All genes described here
were found to be equally expressed in the anterior (prospective
hard) and posterior (prospective soft) palate, with only minor
regional differences (see “Results”).
IMMUNOCYTOCHEMISTRY
A polyclonal rabbit anti-mouse tenascin-W antibody was
obtained from R. Chiquet-Ehrismann (Basel, Switzerland) and
has been characterized before (Scherberich et al., 2004).
Cryosections from paraformaldehyde-fixed mouse embryo heads
Table 1 | Primers used for generation of gene-specific RNA probes for
in situ hybridization.
Mouse fibrillin-1 (Fbn1: NM 007993.2)
Forward: 5′CCGGATCCGGGAACCACCAAGGGTGCTG 3′ (nucleotide:
1364–1383)
Reverse: 5′ CCAAGCTTACGCAGTGGAAGCTGCCGTC 3′ (nucleotide:
1626–1606)
PCR product (without restriction sites): 353 bp
Mouse fibrillin-2 (Fbn2: NM 010181.2)
Forward: 5′ CCGGATCCCGGTGTGTGGACACCGACG 3′ (nucleotide:
4506–4525)
Reverse: 5′ CCAAGCTTCCCCTCGGCACACTCGTCCA 3′ (nucleotide:
4826–4807)
PCR product (without restriction sites): 277 bp
Mouse transforming growth factor-β3 (Tgfb3: NM 009368.3)
Forward: 5′ CCGGATCCCAACCCCAGCTCCAAGCG3′ (nucleotide:
1578–1597)
Reverse: 5′ CCAAGCTTCCAGGTTGCGGAAGCAGT 3′ (nucleotide:
2046–2026)
PCR product (without restriction sites): 469 bp
Mouse transforming growth factor-β1 (Tgfb1: (NM 011577.1)
Forward: 5′ CCGGATCCGTGGACCGCAACAACGCCA 3′ (nucleotide:
1207–1226)
Reverse: 5′ CCAAGCTTGCCGTGAGCTGTGCAGGTG 3′ (nucleotide:
1700–1681)
PCR product (without restriction sites): 488 bp
Mouse fibronectin: (Fn1: NM 010233.1)
Forward: 5′ CCGGATCCGACCGAGCCAGGGAGGTGA 3′ (nucleotide:
1211–1230)
Reverse: 5′ CCAAGCTTGAGCTGGGGCACCTCTGGGA 3′ (nucleotide:
1591–1572)
PCR product (without restriction sites): 453 bp
were blocked with 3% bovine serum albumin in phosphate-
buffered saline (BSA/PBS), incubated with anti-tenascin-W
(1:100 in BSA/PBS) followed by peroxidase-labeled secondary
antibody (Jackson Laboratories; 1:1000 in BSA/PBS). Sections
were developed with 0.18mg/ml chloronaphtol (Merck; stock
solution 3mg/ml in methanol) diluted in PBS, and coun-
terstained with nuclear fast red solution (Sigma, Buchs,
Switzerland).
MICROSCOPY
Slides were viewed with 10× objectives on an Olympus BX-51
microscope. Digital images were recorded using a ProgRes CT3
CMOS camera and ProgRes Capture Pro software (Jenoptik, Jena,
Germany). All slides from one experiment were photographed
at exactly the same camera settings, and resulting images were
processed identically.
CELL CULTURE AND IMMUNOBLOTTING
Cranial fibroblasts were isolated from E14.5 C57BL/6 mouse
embryos. The mid-facial region was dissected from embryo
heads and incubated in 0.05% trypsin-EDTA solution (Gibco;
Invitrogen, Basel, Switzerland) for 1 h at 37◦C, after which the
tissue was triturated by repeated aspiration. Cells were cen-
trifuged, resuspended in Dulbecco’s Minimal Essential Medium
(DMEM; Gibco) containing 10% fetal calf serum (FCS; Gibco),
plated onto 10 cm cell culture dishes, and incubated at 37◦C
with 6% CO2. At confluency, cranial fibroblasts were passaged by
trypsinization. Bmp7 stimulation experiments were performed in
24-well dishes with cells from the second passage. Fibroblasts were
first starved for 24 h in DMEM/0.3% FCS, before the medium
was changed to DMEM/0.3% FCS containing human recom-
binant Bmp7 (PeproTech, Hamburg, Germany; 0, 10, 20, 50,
and 100 ng/ml, respectively). For positive controls, wells were
incubated with DMEM/10% FCS. Cell supernatant was col-
lected from individual wells after 24 h, run on SDS-7.5% poly-
acrylamide gels under reducing conditions, and proteins were
transferred to nitrocellulose. Blots were briefly stained with
0.1% Ponceau Red, and then incubated with rabbit anti-mouse
tenascin-W antiserum (see above) or rat anti-mouse tenascin-C
monoclonal antibody mTn12 (obtained from Ruth Chiquet-
Ehrismann; Aufderheide and Ekblom, 1988), respectively, fol-
lowed by the matching peroxidase-labeled secondary antibodies
(Jackson Laboratories). Blots were developed using ECL reagent
(GE Healthcare, Glattbrugg, Switzerland) and viewed on a Storm
840 Phospho-Imager (Molecular Dynamics; GE Healthcare).
RESULTS
CORRELATION OF FIBRILLIN-2 WITH Tgf -β3 EXPRESSION AT THE
TIME OF PALATAL SHELF FUSION
Tgf-βs are essential for secondary palate formation and fibrillins
are known to bind and activate latent Tgf-βs, but the role of
fibrillins in palatogenesis has not been investigated. We there-
fore compared the expression patterns of fibrillin-1 and -2mRNA
with those of Tgf-β1 and −β3 during palate morphogenesis (see
Figure 1 for overview). In E13.5 wildtype embryos, a weak sig-
nal for fibrillin-1 mRNA overlapped with the one for Tgf-β1 in
the developing maxillary processes above the vertically oriented
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FIGURE 1 | Overview on mouse sections used for this study. Top row:
Hematoxylin/eosin-stained frontal sections though the heads of E13.5 (top
left) and E14.5 (top right) wildtype embryos; level of posterior palate. The
boxed areas correspond to the palatal region depicted in the following
figures. At E13.5 the palatal shelves are vertically oriented on each side of
the tongue, whereas at E14.5 the shelves have elevated above the tongue
and meet at the midline epithelial seam. p, Palatal shelves; t, tongue; n,
nasal cartilage; e, eye; b, forebrain. Bar, 600μm. Bottom row: schematic
drawings of midsagittal sections through the heads of E13.5 (left) and
E14.5 (right) wildtype mouse embryos. The two frontal section planes
used in this study are indicated by dashed lines: a, level of anterior palate;
p, level of posterior palate. Green, nasal cavity; red, tongue; ocre, brain;
blue, elevated palate (E14.5).
palatal shelves (Figures 2A,B). In contrast to fibrillin-1, fibrillin-2
expression was seen within the vertical palatal shelves them-
selves, namely in their proximal-nasal mesenchyme (Figure 2C).
On the other hand, Tgf-β3 mRNA was confined to the pre-
sumptive medial edge epithelial cells at the distal-nasal aspect
of the shelves (Figure 2D). Thus at this stage, only Tgf-β3 and
fibrillin-2 mRNA appeared to be present within palatal shelves,
but no close correlation between their patterns of expression was
observed. One day later (E14.5), however, the signal for fibrillin-
2 was much increased in the now horizontally oriented shelves,
and it was found everywhere in the peripheral mesenchyme that
underlies the palate epithelium (Figure 3C). Thus at this cru-
cial stage immediately before palate fusion, fibrillin-2 was now
expressed in immediate neighborhood to the MEE cells that were
strongly positive for Tgf-β3 (Figure 3D) and more weakly for
Tgf-β1 mRNA (Figure 3B). In contrast to fibrillin-2, fibrillin-1
was not expressed in horizontal palatal shelves (Figure 3A). In
conclusion, the data are consistent with the notion that fibrillin-2
expressed in the mesenchyme might be involved in binding Tgf-
β3 secreted by MEE cells, and in regulating its activity during
palatal shelf fusion.
CONTACT-DEPENDENT EXPRESSION OF FIBRONECTIN BUT NOT
Tgf -β3 BY MIDDLE EDGE EPITHELIAL CELLS
Another known regulator of Tgf-β activity is the ECM and cell
adhesion protein fibronectin, which was reported to be expressed
FIGURE 2 | In situ hybridizations on frontal sections through E13.5
wildtype mouse embryo heads at the level of the posterior palate with
RNA probes specific for (A) fibrillin-1, (B) Tgf-β1, (C) fibrillin-2, and (D)
Tgf-β3. The maxillary processes in (A,B) show increased expression of
fibrillin-1 and Tgf-β1 mRNA, respectively. Note enhanced expression of
fibrillin-2 in the proximal-medial mesenchyme of the palatal shelves (C),
dorsal of the epithelium positive for Tgf-β3 mRNA (D). Maxillary process
(mx), palatal shelf (p), tongue (t). Bars, 250μm.
FIGURE 3 | In situ hybridizations on frontal sections through E14.5
wildtype mouse embryo heads at the level of the posterior palate with
RNA probes specific for (A) fibrillin-1, (B) Tgf-β1, (C) fibrillin-2, and (D)
Tgf-β3. Note the strong expression of fibrillin-2 in the peripheral
mesenchyme of the palatal shelves (C), adjacent to the middle edge
epithelial cells that express Tgf-β3 (D). Palatal shelf (p), tongue (t).
Bars, 250μm.
at the midline before palatal fusion in a Tgf-β3-dependent man-
ner (Martinez-Sanz et al., 2008). We asked whether fibronectin
induction in MEE cells in addition required direct contact of
palatal shelves. This question was addressed by studying Bmp7-
deficient mice, which develop cleft palate due to a delay in
shelf elevation. In E14.5 wildtype (not shown) or heterozygous
Bmp7+/− embryos (Figure 4A), prominent fibronectin mRNA
expression was observed at the midline epithelial seam (MES)
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FIGURE 4 | In situ hybridization for fibronectin (FN; A,B) and Tgf-β3
(C,D) mRNA, respectively, on frontal sections through the heads of
E14.5 Bmp7+/− (A,C) and Bmp7−/− (B,D) mouse embryos (anterior
level). Note fibronectin mRNA expressed by midline epithelial cells in the
Bmp7+/− embryo (A), whereas epithelial expression is almost absent in
the palatal shelves of the Bmp7−/− embryo at the same stage (B).
Maxillary process (mx), palatal shelf (p), tongue (t). Bar, 200μm.
of opposing shelves, where it overlapped with the Tgf-β3 signal
(Figure 4C). In contrast, little fibronectin mRNA was found
in the still vertical palatal shelves of E14.5 Bmp7−/− embryos
(Figure 4B), although Tgf-β3 mRNA was normally expressed in
the presumptive MEE cells (Figure 4D; compare to E13.5 wild-
type embryo in Figure 2D). Thus, whereas these cells started
producing Tgf-β3 mRNA even before shelves elevate and meet,
they expressed fibronectin only upon contact of the two shelves at
the midline; the latter event failed to occur in Bmp7−/− embryos.
Since, like fibrillins, fibronectin can bind Tgf-βs and modulate
their activation, its localized and contact-dependent expression
at the midline might be related to the function of Tgf-β3 during
palatal shelf fusion.
EXPRESSION OF TENASCINS DURING PALATOGENESIS IN
WILDTYPE AND Bmp7 -DEFICIENT MOUSE EMBRYOS
Of the four members of the tenascin family of ECM glycoproteins
(Chiquet-Ehrismann and Chiquet, 2003), the genes of two are
expressed in distinct spatial and temporal patterns during mor-
phogenesis of the secondary palate in the mouse embryo, namely
tenascin-C and tenascin-W, as evidenced by in situ hybridiza-
tion (Figure 5). At E13.5, before elevation of the palatal shelves,
tenascin-C mRNA accumulated in the mesenchyme close to the
nasal and distal surface of the shelf, i.e., underneath the prospec-
tive MEE cells (Figure 5A). Accordingly, after shelf elevation at
E14.5, tenascin-C mRNA was enriched in the palate mesenchyme
in a vertical stripe around the MES (Figure 5B). A second area
of tenascin-C expression was observed at E13.5 near the devel-
oping maxillary processes, and at E15 sharply outlined their
periphery (Figures 5A,B). In contrast, tenascin-W mRNA was
detected at both stages within the forming maxillary processes
(Figures 5C,D). Weak mesenchymal tenascin-W expression was
FIGURE 5 | In situ hybridization for tenascin-C (TNC; A,B) and
tenascin-W (TNW; C,D) mRNA, respectively, on frontal sections
through the heads of E13.5 (A,C) and E14.5 (B,D) wildtype mouse
embryos (posterior level). Maxillary process (mx), palatal shelf (p),
tongue (t). Bar, 250μm.
also found in the proximal-nasal quadrant of the vertical shelves
at E13.5, and after their elevation this pattern developed into a
prominent horizontal stripe in the nasal half of the secondary
palate (Figure 5D). Thus at E14.5, tenascin-W positive areas
essentially corresponded to the osteogenic domains of the devel-
oping palate.
Since tenascin genes are known to be transcriptional targets of
the Tgf-β/Bmp growth factor family, we then asked whether their
expression was altered in Bmp7-deficient embryos, which develop
cleft palate due to delayed shelf elevation. As can be seen from
Figures 6A,C, at E14.5 the expression of both tenascin-C and -W
was very similar in the elevated palate of heterozygous Bmp7+/−
embryos when compared to wildtype (cf. Figures 5B,D). In
Bmp7−/− embryos at E14.5 (Figure 6B), tenascin-C was found
to be expressed in the still vertical shelves in a pattern reminis-
cent to that of wildtype embryos at E13.5 (cf. Figure 5A). In
contrast, tenascin-W expression in palatal shelves of Bmp7−/−
embryos appeared to be diminished not only relative to het-
erozygous embryos of the same stage (Figures 6C,D), but also
when compared to the vertical shelves of E13.5 wildtype embryos
(cf. Figure 5C).
To investigate a possibly aberrant expression of tenascin-W in
palatal shelves of Bmp7-deficient embryos also on the protein
level, we compared frontal sections from control and Bmp7-
deficient E13.5 embryo heads (i.e., before palate elevation in the
wildtype) by immunohistochemistry. Tenascin-C protein distri-
bution turned out to be similar in palatal shelves from heterozy-
gous versus Bmp7−/− embryos at both the anterior and posterior
level at this stage (not shown), and it fitted with the mRNA
expression pattern observed previously by in situ hybridization
(cf. Figure 5). In contrast, tenascin-W protein was distributed
differently in the anterior palate of E13.5 Bmp7−/− embryos
when compared to the wildtype control (Figures 7A,B), and
in the posterior palate its expression was considerably reduced
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FIGURE 6 | In situ hybridization for tenascin-C (TNC; A,B) and
tenascin-W (TNW; C,D) respectively, on frontal sections through the
heads of E14.5 Bmp7+/− (A,C) and Bmp7−/− (B,D) mouse embryos. In
this anterior section, a low tenascin-C signal is seen in the maxillary
processes of the heterozygous embryo, whereas expression in the palatal
shelves is identical to the posterior level (cf. Figure 5). Note low expression
of tenascin-W in the palatal shelves of the Bmp7−/− embryo (D) compared
to Bmp7+/− (C) or wildtype (cf. Figure 1). Maxillary process (mx), palatal
shelf (p), tongue (t). Bar, 200μm.
FIGURE 7 | Immunocytochemistry for tenascin-W on frontal sections
of E13.5 Bmp7+/+ (A,B) and Bmp7−/− (C,D) embryos. Sections through
the anterior (A,C) and the posterior (B,D) palate are shown. Note
tenascin-W protein staining extending into the palatal shelf in the Bmp7+/+
embryo (A), whereas it remains focussed to the region of the maxillary
process in the Bmp7−/− embryo (B). In the posterior palate, tenascin-W
protein expression is reduced in the maxillary process of the Bmp7−/− (D)
compared to the Bmp7+/+ (C) embryo (arrows). mx, Maxillary process; p,
palatal shelf; t, tongue; tb, tooth bud; md, mandible; m, Meckel’s cartilage.
Bar, 200μm.
in the maxillary process (Figures 7C,D). These findings are
in accordance with the hypothesis that tenascin-W (but not
tenascin-C) might be a downstream target of Bmp7 associated
with palatal shelf reorientation.
FIGURE 8 | Immunoblotting for tenascin-W (TnW) and tenascin-C
(TnC) in media conditioned by mouse embryonic cranial fibroblasts,
which were stimulated with the indicated concentrations of Bmp7 for
24h. The last lane of each blot shows a control culture stimulated with 10%
fetal bovine serum (FCS). Below each immunoblot, Ponceau Red staining of
the corresponding membrane is shown; medium-derived bovine serum
albumin (BSA) was used for loading control. Numbers at right indicate
protein molecular weights in kDa.
INDUCTION OF TENASCIN-W BUT NOT TENASCIN-C BY Bmp7
IN EMBRYONIC CRANIAL FIBROBLASTS in vitro
Since we observed an altered pattern of expression for tenascin-
W in the palatal region of Bmp7−/− embryos, we asked whether
this ECM protein was a direct target of Bmp7 signaling. To this
aim, cranial fibroblasts were isolated from the heads of E14.5
wildtype embryos, and cultured under low serum conditions in
the presence of increasing concentrations of recombinant Bmp7
(rBMP7). For negative and positive controls, cells were grown in
either low (0.3%) or high (10%) fetal calf serum, respectively. The
medium was collected after 24 h, and secreted tenascin-C and -W
protein was analyzed by immunoblotting. As is evident from
Figure 8, already 10 ng/ml rBMP7 strongly stimulated tenascin-
W (180 kDa) production by cranial fibroblasts compared to the
low serum control; maximal induction was seen with 50 ng/ml. In
contrast, 100 ng/ml rBMP7 were required to detect a weak signal
for the small (200 kDa) but not the large (250 kDa) splice variant
of tenascin-C. Secretion of both tenascins was strongly induced by
10% serum (Figure 8). Thus, Bmp7 appears to directly regulate
the production of tenascin-W but not tenascin-C, which agrees
with the results obtained from the Bmp7−/− embryos.
DISCUSSION
INTERACTION BETWEEN GROWTH FACTORS AND EXTRACELLULAR
MATRIX DURING PALATOGENESIS
Cleft lip, with or without cleft palate, and isolated cleft palate
occur with a frequency of 1–2 in thousand live births. They
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represent the most common craniofacial birth defects in humans
(Mitchell, 2009). Genetic and environmental factors cause these
congenital anomalies (Jugessur and Murray, 2005). It has been
noted that various failures of either palatal shelf growth, ele-
vation, adhesion, or the lack of mesenchymal differentiation
and disappearance of the MES can cause cleft palate (Gritli-
Linde, 2007). Thus, the study of palatogenesis and the etiology
of cleft palate are key to understanding oral malformations. The
essential roles of Tgf-βs and Bmps during palatogenesis have
been investigated by various authors in the developing mouse
embryo (Proetzel et al., 1995; Martinez-Alvarez et al., 2000;
Nawshad et al., 2004; Zouvelou et al., 2009a). It is well estab-
lished that it is a major function of these growth factors to
regulate ECM synthesis and turnover (Verrecchia and Mauviel,
2007; Tucker and Chiquet-Ehrismann, 2009). However, it is com-
pletely unknown so far whether changes in the expression of
specific ECM components might be causally involved in the
craniofacial and other malformations observed in Tgf-β– or
Bmp-deficient mice. In other words, maybe with the exception
of the well-established function of Tgf-β3 during palatal fusion,
it is still largely a mystery how a growth factor deficiency even-
tually translates into a specific congenital malformation. Since
ECM proteins are transcriptional targets of Tgf-β/Bmp growth
factors and essential for tissue structure, as well as for cell
adhesion and migration, it is obvious to hypothesize that they
might be causally involved in linking growth factor deficiency
to CLP.
WHY STUDY TENASCINS AND FIBRILLINS IN THE CONTEXT OF
PALATOGENESIS?
Although numerous extracellular proteins are expressed in the
developing orofacial complex, we have so far focused our atten-
tion mainly on two families of ECM glycoproteins, namely
tenascins and fibrillins. Tenascins belong to the so-called “matri-
cellular” ECM proteins that modulate cell-ECM interactions
and ECM assembly (Chiquet-Ehrismann and Chiquet, 2003).
Of the four family members, two are expressed in the devel-
oping secondary palate, namely tenascin-C and tenascin-W. In
contrast to the prototype adhesive ECM protein fibronectin,
both these tenascins are “anti-adhesive” in a context-dependent
manner, i.e., they interfere with fibronectin-mediated cell spread-
ing (Chiquet-Ehrismann et al., 1988; Brellier et al., 2012).
Thus, they might be involved in tissue reorganization dur-
ing palatogenesis. Fibrillins, on the other hand, are cysteine-
rich glycoproteins present in extracellular microfibrils in elastic
and nonelastic tissues (Keene et al., 1991; Ramirez and Sakai,
2010). These ECM components not only play a structural
role in integrating connective tissues, but they also have an
important regulatory function in modulating the distribution
and activation of growth factors of the Tgf-β/Bmp family,
which in turn regulate ECM formation and cell differentia-
tion (Ramirez and Rifkin, 2009). Mutations in the Fibrillin-
1 gene result in a complex connective tissue disorder called
Marfan syndrome with prevalent cardiovascular, ophthalmo-
logic and orthopaedic signs (Lee et al., 1991). These muta-
tions also cause dysregulation of Tgf-β/Bmp activation and
signaling (Nistala et al., 2010), resulting in apoptosis in the
developing lung (Neptune et al., 2003). Mutations in Fibrillin-2
are responsible for a related, but less severe condition, namely
congenital contractural arachnodactyly with mostly muscu-
loskeletal manifestations (Lee et al., 1991; Ramirez and Rifkin,
2009). It is therefore reasonable to believe that fibrillins modulate
the activity of Tgf-β/Bmp growth factors also during craniofacial
morphogenesis.
FIBRILLIN-2 AND FIBRONECTIN: MODULATORS OF Tgf-ß3
ACTIVITY DURING PALATAL SHELF FUSION?
Growth factors of the Tgf-β family are secreted as inactive com-
plexes with latent Tgf-β binding protein (LTBP), which itself can
bind to fibrillin or fibronectin microfibrils (Ramirez and Rifkin,
2009). Activation of ECM-bound, latent growth factor complexes
involve their interaction with integrins on cell surfaces and the
application of cellular force (Wipff et al., 2007). In the com-
plex process of activation, fibrillins (Ramirez and Rifkin, 2009)
and fibronectin (Fontana et al., 2005) play an important role
by presenting latent growth factor complexes to cells, thereby
controlling bioavailability of active Tgf-βs. Interestingly, it has
been shown recently that fibrillin-1 and fibrillin-2 regulate Tgf-β
and Bmp activity in distinct ways: Whereas both fibrillins stim-
ulate Tgf-β activation, binding of Bmps to fibrillin-1 (but not
fibrillin-2) reduces activity of the latter growth factors (Nistala
et al., 2010). It is therefore important to know how fibrillin-1
and -2 are expressed during palatogenesis in relation to growth
factors known to be involved in this morphogenetic process.
Here we show that fibrillin-1 expression decreases whereas that
of fibrillin-2 increases during palatogenesis. This observation fits
with the notion that both Tgf-βs and Bmps need to be acti-
vated during the process. In addition, we found that fibrillin-2
was expressed in the mesenchyme adjacent to the MES before
palatal shelf fusion. Moreover fibronectin, which is also known
to positively regulate Tgf-β activation (Fontana et al., 2005),
was expressed by MEE cells upon their contact. Thus, fibrillin-
2 and fibronectin might be important for the essential role of
Tgf-β3 during palatal shelf fusion. This hypothesis could be
tested, e.g., in tissue culture, by examining the fusion capacity
of fibrillin-2/Tgf-β3 double deficient palatal shelves in the pres-
ence or absence of Tgf-β3. Alternatively, it would be interesting to
test whether heterozygous Tgf -β3+/− embryos (which develop
normally) would present with cleft palate on a fibrillin-2−/−
background.
TENASCIN-W: A POSSIBLE DOWNSTREAM TARGET OF Bmp7
DURING PALATE REORIENTATION?
Because of its region-specific expression in embryonic palatal
shelves before and after their reorientation, tenascin-C has been
implicated in morphogenesis of the secondary palate more than
20 years ago. Since then, however, tenascin-C knockout mice
have been generated, and these do not exhibit overt craniofacial
abnormalities (Saga et al., 1992; Forsberg et al., 1996). A possible
explanation for the surprisingly mild phenotype of tenascin-C-
deficient mice might be compensation by other ECM proteins. A
likely candidate is the functionally related tenascin-W (gene name
Tnn), whose expression is similar to that of tenascin-C, especially
in osteogenic regions of the embryo (Scherberich et al., 2004).
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In the mouse head, tenascin-W expression starts in the max-
illary processes at E13.5 (Scherberich et al., 2004), and we
show here that tenascin-W mRNA and protein is detected in
a distinct spatial-temporal pattern during development of the
secondary palate. In E13.5 wildtype embryos, tenascin-W is
found in the vertical palatal shelves anteriorly in the nasal
mesenchyme, and more posteriorly in the ossifying region of
the maxillary processes. After shelf reorientation, tenascin-W is
expressed in the dorsal half of the secondary palate, partially
(but not completely) overlapping with tenascin-C. In Bmp7−/−
mice in which palatal shelf reorientation is delayed, tenascin-W
(but not tenascin-C) protein appeared to be distributed differ-
ently in the anterior shelf, and its amount was reduced more
posteriorly. In perfect agreement with these results, the secre-
tion of tenascin-W but not tenascin-C protein was found to
be induced by recombinant Bmp7 in cranial fibroblasts iso-
lated from E14.5 mouse embryos. We therefore speculate that
tenascin-W might be a downstream effector of Bmp7 signal-
ing, and that cleft palate in the Bmp7 knockout mouse might
in part be caused by a misexpression of tenascin-W. To estab-
lish a causal relationship, however, it needs to be tested whether
Bmp7, like Bmp2 (Tucker and Chiquet-Ehrismann, 2009), reg-
ulates tenascin-W at the transcriptional level, and whether
tenascin-W-deficient mice exhibit a palate phenotype. These
experiments are underway.
CONCLUSIONS AND PERSPECTIVES
The present study was undertaken to obtain first evidence for
a functional interaction between Tgf-β/Bmp growth factors and
selected ECM glycoproteins during morphogenesis of the sec-
ondary palate in mammalian embryos. Based on our results, we
speculate that misexpression of the “matricellular” ECM protein
tenascin-W might be involved in causing the cleft palate phe-
notype of the Bmp7 knockout mouse, and that fibrillin-2 and
fibronectin could be important for the activation of Tgf-β3 at
the palatal midline during fusion. Our present findings provide
the basis for testable hypotheses concerning the precise function
of ECM components as downstream effectors of growth factor
signaling during palatogenesis.
ACKNOWLEDGMENTS
We thank Ruth Chiquet-Ehrismann for providing us with
antibodies to mouse tenascin-C and tenascin-W, and Sabrina
Ruggiero for excellent technical help. This work was supported by
grants from the European Orthodontic Society to Pawel Pazera
and from the Swiss National Fund to Daniel Graf.
REFERENCES
Alappat, S., Zhang, Z. Y., and Chen, Y. P.
(2003). Msx homeobox gene family
and craniofacial development. Cell
Res. 13, 429–442.
Alberts, B., Johnson, A., Lewis, J., Raff,
M., Roberts, K., and Walter, P.
(2008).Molecular Biology of the Cell,
5th Edn. chapter 19. New York, NY:
Garland Science.
Aufderheide, E., and Ekblom, P. (1988).
Tenascin during gut development:
appearance in the mesenchyme,
shift in molecular forms, and
dependence on epithelial-
mesenchymal interactions. J.
Cell Biol. 107, 2341–2349.
Brellier, F., Martina, E., Chiquet, M.,
Ferralli, J., van der Heyden, M.,
Orend, G., Schittny, J. C., Chiquet-
Ehrismann, R., and Tucker, R. P.
(2012). The adhesion modulating
properties of tenascin-W. Int. J. Biol.
Sci. 8, 187–194.
Chiquet-Ehrismann, R., and Chiquet,
M. (2003). Tenascins: regulation
and putative functions during
pathological stress. J. Pathol. 200,
488–499.
Chiquet-Ehrismann, R., Kalla, P.,
Pearson, C. A., Beck, K., and
Chiquet, M. (1988). Tenascin inter-
feres with fibronectin action. Cell
53, 383–390.
Dallas, S. L., Sivakumar, P., Jones, C.
J., Chen, Q., Peters, D. M., Mosher,
D. F., Humphries, M. J., and Kielty,
C. M. (2005). Fibronectin regu-
lates latent transforming growth
factor-beta (TGF beta) by con-
trolling matrix assembly of latent
TGF beta-binding protein-1. J. Biol.
Chem. 280, 18871–18880.
Ferguson, M. W. (1988). Palate devel-
opment. Development 103(Suppl.),
41–60.
Fluck, M., Tunc-Civelek, V., and
Chiquet, M. (2000). Rapid and
reciprocal regulation of tenascin-C
and tenascin-Y expression by load-
ing of skeletal muscle. J. Cell Sci.
113(Pt 20), 3583–3591.
Fontana, L., Chen, Y., Prijatelj, P.,
Sakai, T., Fassler, R., Sakai, L.
Y., and Rifkin, D. B. (2005).
Fibronectin is required for integrin
alphavbeta6-mediated activation
of latent TGF-beta complexes
containing LTBP-1. FASEB J. 19,
1798–1808.
Forsberg, E., Hirsch, E., Frohlich, L.,
Meyer, M., Ekblom, P., Aszodi,
A., Werner, S., and Fassler, R.
(1996). Skin wounds and severed
nerves heal normally in mice lack-
ing tenascin-C. Proc. Natl. Acad. Sci.
U.S.A. 93, 6594–6599.
Gato, A., Martinez, M. L., Tudela, C.,
Alonso, I., Moro, J. A., Formoso,
M. A., Ferguson, M. W., and
Martinez-Alvarez, C. (2002).
TGF-beta(3)-induced chondroitin
sulphate proteoglycan mediates
palatal shelf adhesion. Dev. Biol.
250, 393–405.
Gritli-Linde, A. (2007). Molecular con-
trol of secondary palate develop-
ment. Dev. Biol. 301, 309–326.
Huang, W., Chiquet-Ehrismann, R.,
Moyano, J. V., Garcia-Pardo, A.,
and Orend, G. (2001). Interference
of tenascin-C with syndecan-4
binding to fibronectin blocks cell
adhesion and stimulates tumor
cell proliferation. Cancer Res. 61,
8586–8594.
Huang, X., Yokota, T., Iwata, J., and
Chai, Y. (2011). Tgf-beta-mediated
FasL-Fas-Caspase pathway is crucial
during palatogenesis. J. Dent. Res.
90, 981–987.
Ingraham, C. R., Kinoshita, A., Kondo,
S., Yang, B., Sajan, S., Trout, K. J.,
Malik, M. I., Dunnwald, M., Goudy,
S. L., Lovett, M., Murray, J. C.,
and Schutte, B. C. (2006). Abnormal
skin, limb and craniofacial morpho-
genesis in mice deficient for inter-
feron regulatory factor 6 (Irf6). Nat.
Genet. 38, 1335–1340.
Iozzo, R. V., Zoeller, J. J., and Nystrom,
A. (2009). Basement membrane
proteoglycans: modulators Par
Excellence of cancer growth
and angiogenesis. Mol. Cells 27,
503–513.
Iwata, J., Parada, C., and Chai, Y.
(2011). The mechanism of TGF-
beta signaling during palate devel-
opment. Oral Dis. 17, 733–744.
Jugessur, A., and Murray, J. C. (2005).
Orofacial clefting: recent insights
into a complex trait. Curr. Opin.
Genet. Dev. 15, 270–278.
Kaartinen, V., and Warburton, D.
(2003). Fibrillin controls TGF-beta
activation. Nat. Genet. 33, 331–332.
Keene, D. R., Maddox, B. K., Kuo, H.
J., Sakai, L. Y., and Glanville, R.
W. (1991). Extraction of extend-
able beaded structures and their
identification as fibrillin-containing
extracellular matrix microfibrils. J.
Histochem. Cytochem. 39, 441–449.
Koch, M., Bohrmann, B., Matthison,
M., Hagios, C., Trueb, B., and
Chiquet, M. (1995). Large and
small splice variants of collagen
XII: differential expression and lig-
and binding. J. Cell Biol. 130,
1005–1014.
Kondo, S., Schutte, B. C., Richardson,
R. J., Bjork, B. C., Knight, A. S.,
Watanabe, Y., Howard, E., de Lima,
R. L., Daack-Hirsch, S., Sander, A.,
McDonald-McGinn, D. M., Zackai,
E. H., Lammer, E. J., Aylsworth,
A. S., Ardinger, H. H., Lidral,
A. C., Pober, B. R., Moreno, L.,
Arcos-Burgos, M., Valencia, C.,
Houdayer, C., Bahuau, M., Moretti-
Ferreira, D., Richieri-Costa, A.,
Dixon, M. J., and Murray, J. C.
(2002). Mutations in IRF6 cause
Van der Woude and popliteal ptery-
gium syndromes. Nat. Genet. 32,
285–289.
Larsen, M., Artym, V. V., Green, J.
A., and Yamada, K. M. (2006).
The matrix reorganized: extracellu-
lar matrix remodeling and integrin
signaling. Curr. Opin. Cell Biol. 18,
463–471.
Lee, B., Godfrey, M., Vitale, E., Hori,
H., Mattei, M. G., Sarfarazi, M.,
Tsipouras, P., Ramirez, F., and
Frontiers in Physiology | Craniofacial Biology September 2012 | Volume 3 | Article 377 | 8
d’Amaro et al. Extracellular matrix in palate morphogenesis
Hollister, D. W. (1991). Linkage
of Marfan syndrome and a phe-
notypically related disorder to two
different fibrillin genes. Nature 352,
330–334.
Maier, S., Lutz, R., Gelman, L., Sarasa-
Renedo, A., Schenk, S., Grashoff, C.,
and Chiquet, M. (2008). Tenascin-C
induction by cyclic strain requires
integrin-linked kinase. Biochim.
Biophys. Acta 1783, 1150–1162.
Martinez-Alvarez, C., Tudela, C., Perez-
Miguelsanz, J., O’Kane, S., Puerta,
J., and Ferguson, M. W. (2000).
Medial edge epithelial cell fate dur-
ing palatal fusion. Dev. Biol. 220,
343–357.
Martinez-Sanz, E., Del Rio, A.,
Barrio, C., Murillo, J., Maldonado,
E., Garcillan, B., Amoros, M.,
Fuerte, T., Fernandez, A., Trinidad,
E., Rabadan, M. A., Lopez, Y.,
Martinez, M. L., and Martinez-
Alvarez, C. (2008). Alteration of
medial-edge epithelium cell adhe-
sion in two Tgf-beta3 null mouse
strains. Differentiation 76, 417–430.
Meng, L., Bian, Z., Torensma, R.,
and Von den Hoff, J. W. (2009).
Biological mechanisms in palatoge-
nesis and cleft palate. J. Dent. Res.
88, 22–33.
Mitchell, L. E. (2009). Epidemiology
of Cleft Lip and Palate. In
Comprehensive Cleft Care. Toronto,
ON: McGraw-Hill.
Morris-Wiman, J., and Brinkley, L.
(1992). An extracellular matrix
infrastructure provides support
for murine secondary palatal
shelf remodelling. Anat. Rec. 234,
575–586.
Mossey, P. A., Little, J., Munger, R.
G., Dixon, M. J., and Shaw, W. C.
(2009). Cleft lip and palate. Lancet
374, 1773–1785.
Mott, J. D., and Werb, Z. (2004).
Regulation of matrix biology by
matrix metalloproteinases. Curr.
Opin. Cell Biol. 16, 558–564.
Nawshad, A. (2008). Palatal seam dis-
integration: to die or not to die? that
is no longer the question. Dev. Dyn.
237, 2643–2656.
Nawshad, A., and Hay, E. D. (2003).
TGFbeta3 signaling activates tran-
scription of the LEF1 gene to induce
epithelial mesenchymal trans-
formation during mouse palate
development. J. Cell Biol. 163,
1291–1301.
Nawshad, A., LaGamba, D., and Hay,
E. D. (2004). Transforming growth
factor beta (TGFbeta) signalling
in palatal growth, apoptosis and
epithelial mesenchymal transforma-
tion (EMT). Arch. Oral Biol. 49,
675–689.
Neptune, E. R., Frischmeyer, P. A.,
Arking, D. E., Myers, L., Bunton, T.
E., Gayraud, B., Ramirez, F., Sakai,
L. Y., and Dietz, H. C. (2003).
Dysregulation of TGF-beta activa-
tion contributes to pathogenesis in
Marfan syndrome. Nat. Genet. 33,
407–411.
Nistala, H., Lee-Arteaga, S., Smaldone,
S., Siciliano, G., Carta, L., Ono,
R. N., Sengle, G., Arteaga-Solis, E.,
Levasseur, R., Ducy, P., Sakai, L.
Y., Karsenty, G., and Ramirez, F.
(2010). Fibrillin-1 and -2 differen-
tially modulate endogenous TGF-
beta and BMP bioavailability during
bone formation. J. Cell Biol. 190,
1107–1121.
Proetzel, G., Pawlowski, S. A., Wiles,
M. V., Yin, M., Boivin, G. P.,
Howles, P. N., Ding, J., Ferguson,
M. W., and Doetschman, T. (1995).
Transforming growth factor-beta 3
is required for secondary palate
fusion. Nat. Genet. 11, 409–414.
Ramirez, F., and Rifkin, D. B. (2009).
Extracellular microfibrils: contex-
tual platforms for TGFbeta and
BMP signaling.Curr. Opin. Cell Biol.
21, 616–622.
Ramirez, F., and Sakai, L. Y. (2010).
Biogenesis and function of fibrillin
assemblies. Cell Tissue Res. 339,
71–82.
Saga, Y., Yagi, T., Ikawa, Y., Sakakura, T.,
and Aizawa, S. (1992). Mice develop
normally without tenascin. Genes
Dev. 6, 1821–1831.
Satokata, I., and Maas, R. (1994). Msx1
deficient mice exhibit cleft palate
and abnormalities of craniofacial
and tooth development. Nat. Genet.
6, 348–356.
Scherberich, A., Tucker, R. P.,
Samandari, E., Brown-Luedi,
M., Martin, D., and Chiquet-
Ehrismann, R. (2004). Murine
tenascin-W: a novel mammalian
tenascin expressed in kidney and
at sites of bone and smooth mus-
cle development. J. Cell Sci. 117,
571–581.
Taya, Y., O’Kane, S., and Ferguson,
M. W. (1999). Pathogenesis of cleft
palate in TGF-beta3 knockout mice.
Development 126, 3869–3879.
Tucker, R. P., and Chiquet-Ehrismann,
R. (2009). The regulation of
tenascin expression by tissue
microenvironments. Biochim.
Biophys. Acta 1793, 888–892.
Verrecchia, F., and Mauviel, A. (2007).
Transforming growth factor-beta
and fibrosis. World J. Gastroenterol.
13, 3056–3062.
Wipff, P. J., Rifkin, D. B., Meister, J. J.,
and Hinz, B. (2007). Myofibroblast
contraction activates latent
TGF-beta1 from the extracel-
lular matrix. J. Cell Biol. 179,
1311–1323.
Wyatt, A. W., Osborne, R. J., Stewart,
H., and Ragge, N. K. (2010). Bone
morphogenetic protein 7 (BMP7)
mutations are associated with vari-
able ocular, brain, ear, palate, and
skeletal anomalies. Hum. Mutat. 31,
781–787.
Xu, X., Han, J., Ito, Y., Bringas, P.
Jr., Urata, M. M., and Chai, Y.
(2006). Cell autonomous require-
ment for Tgfbr2 in the disappear-
ance of medial edge epithelium dur-
ing palatal fusion. Dev. Biol. 297,
238–248.
Zhang, G., Young, B. B., Ezura,
Y., Favata, M., Soslowsky, L. J.,
Chakravarti, S., and Birk, D. E.
(2005). Development of tendon
structure and function: regula-
tion of collagen fibrillogenesis.
J. Musculoskelet. Neuronal Interact.
5, 5–21.
Zouvelou, V., Luder, H. U., Mitsiadis, T.
A., and Graf, D. (2009a). Deletion
of BMP7 affects the development of
bones, teeth, and other ectodermal
appendages of the orofacial com-
plex. J. Exp. Zool. B, Mol. Dev. Evol.
312B, 361–374.
Zouvelou, V., Passa, O., Segklia, K.,
Tsalavos, S., Valenzuela, D. M.,
Economides, A. N., and Graf, D.
(2009b). Generation and functional
characterization of mice with a
conditional BMP7 allele. Int. J. Dev.
Biol. 53, 597–603.
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 19 June 2012; accepted: 04
September 2012; published online: 24
September 2012.
Citation: d’Amaro R, Scheidegger R,
Blumer S, Pazera P, Katsaros C, Graf D
and Chiquet M (2012) Putative func-
tions of extracellular matrix glycopro-
teins in secondary palate morphogenesis.
Front. Physio. 3:377. doi: 10.3389/fphys.
2012.00377
This article was submitted to Frontiers
in Craniofacial Biology, a specialty of
Frontiers in Physiology.
Copyright © 2012 d’Amaro,
Scheidegger, Blumer, Pazera, Katsaros,
Graf and Chiquet. This is an open-access
article distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and subject to any copyright notices
concerning any third-party graphics etc.
www.frontiersin.org September 2012 | Volume 3 | Article 377 | 9
